Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levels

Bibliography

• Kim B, Eggel A, Tarchevskaya SS, et al. Accelerated disassembly of IgE-receptor complexes by a disruptive macromolecular inhibitor. Nature 2012;491(7425):613-17
   PubMed Web of Science ®Google Scholar
• Yalcin AD, Bisgin A. Anti-IgE therapy in severe allergic conditions. J Allergy Ther 2012;3:120
   Google Scholar
• Yalcin AD, Bisgin A, Gorczynski RM. IL-8, IL10, TGF-β and GCSF levels were increased in severe persistent allergic asthma patients with the anti-IgE treatment. Mediators Inflamm 2012;2012:720976
   PubMed Web of Science ®Google Scholar
• Yalcin AD, Gumuslu S, Parlak GE, et al. Systemic levels of ceruloplasmin oxidase activity ın allergic asthma and allergic rhinitis. Immunopharmacol Immunotoxicol 2012;34(6):1047-53
   PubMed Web of Science ®Google Scholar
• Yalcin AD, Bisgin A. The relation of sTRAIL levels and quality of life ın omalizumab using severe persistent allergic asthma patients. (WISC 2012: WAO Outstanding Abstract Award). Med Sci Monit 2012;18(8):LE9-10
   PubMed Web of Science ®Google Scholar
• Chang TW. Developing antibodies for targeting immunoglobulin and membrane bound immunoglobulin E. Allergy Asthma Proc 2006;27:S7-S14
   PubMed Web of Science ®Google Scholar
• Chang TW, Shiung YY. Anti IgE as a mast cell stabilizing therapeutic agent. J Allergy Clin Immunol 2006;117:1203-12
   PubMed Web of Science ®Google Scholar
• Adcock LM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008;372(9643):1073-87
   PubMed Web of Science ®Google Scholar
• Heaney GL, Robinson DS. Severe asthma treatment: need for characterising patients. Lancet 2005;365(9463):974-6
   PubMed Web of Science ®Google Scholar
• Eisner MD, Zazzali JL, Miller MK, et al. Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS Study. J Asthma 2012;49(6):642-8
   PubMed Web of Science ®Google Scholar
• Long AA, Fish JE, Rahmaoui A, et al. Baseline characteristics of patients enrolled in EXCELS: a cohort study. Ann Allergy Asthma Immunol 2009;103(3):212-19
   PubMed Web of Science ®Google Scholar
• Ali AK, Hartzema AG. Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting. J Asthma Allergy 2012;5:1-9
   PubMedGoogle Scholar
• Farrell RJ, Lamb J. Prophylactic anticoagulation in heterozygous protein C deficiency. Lancet 1993;341(8847):754
   PubMed Web of Science ®Google Scholar
• Harper PL, Edgar PF, Luddington RJ, et al. Protein C deficiency and portal thrombosis in liver transplantation in children. Lancet 1988;2(8617):924-7
   PubMed Web of Science ®Google Scholar
• Koduri G, Norton S, Young A, et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford) 2010;49:1483-9
   PubMed Web of Science ®Google Scholar
• Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol 2000;18:157-62
   PubMed Web of Science ®Google Scholar
• Anderson WJ, Short PM, Williamson PA, et al. Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trial. Chest 2012;142(6):1553-61
   PubMed Web of Science ®Google Scholar
• Kim CK. Eosinophil-derived neurotoxin: a novel biomarker for diagnosis and monitoring of asthma. Korean J Pediatr 2013;56(1):8-12
   PubMedGoogle Scholar
• Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Bodzenta-Lukaszyk A. Airway inflammation and eotaxin in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy. Adv Med Sci 2011;56(2):318-22
   PubMed Web of Science ®Google Scholar
• Taylor DR, Pijnenburg MW, Smith AD, et al. Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 2006;61:817-27
   PubMed Web of Science ®Google Scholar
• Eisner MD, Yegin A, Trzaskoma B, et al. Severity of asthma score predicts clinical outcomes in patients with moderate to severe persistent asthma severity of asthma score predicts outcomes. Chest 2012;141(1):58-65
   PubMed Web of Science ®Google Scholar
• Gershon AS, Victor JC, Guan J, et al. Pulmonary function testing in the diagnosis of asthmapulmonary function testing in asthma diagnosis: a population study. Chest 2012;141(5):1190-6
   PubMed Web of Science ®Google Scholar
• Scott S, Currie J, Albert P, et al. Risk of misdiagnosis, health-related quality of life, and BMI in patients who are overweight with doctor-diagnosed asthmaquality of life in obese patients with asthma. Chest 2012;141(3):616-24
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma: GINA Report, Global Strategy for Asthma Management and Prevention – updated. 2012. Available from: www.ginasthma.org
   Google Scholar
• Krause K, Metz M, Makris M, et al. The role of interleukin-1 in allergy-related disorders. Curr Opin Allergy Clin Immunol 2012;12(5):477-84
   PubMed Web of Science ®Google Scholar
• Yalcin AD, Karakas AA, Soykam G, et al. A case of toxic epidermal necrolysis with diverse etiologies: successful treatment with ıntravenous ımmunoglobulin and pulse prednisolone and effects on sTRAIL and sCD200 levels. Clin Lab 2013;59:681-5
   PubMed Web of Science ®Google Scholar
• Gorczynski RM. CD200:CD200R-mediated regulation of ımmunity. ISRN Immunol 2012; doi:10.5402/2012/682168
   Google Scholar
• Korn S, Hübner M, Jung M, et al. Severe and uncontrolled adult asthma is associated with vitamin D insufficiency and deficiency. Respir Res 2013;14(1):25
   PubMed Web of Science ®Google Scholar
• Chambers ES, Nanzer AM, Richards DF, et al. Serum 25-dihydroxyvitamin D levels correlate with CD4(+)Foxp3(+) T-cell numbers in moderate/severe asthma. J Allergy Clin Immunol 2012;130(2):542-4
   PubMed Web of Science ®Google Scholar
• Yalcin AD, Bisgin A, Cetinkaya R, et al. Clinical course and side effects of omalizumab in patients with severe persistent asthma. Clin Lab 2013;59:71-7
   PubMed Web of Science ®Google Scholar
• Yalcin AD, Ucar S, Gumuslu S, Strauss L. Effects of omalizumab on eosinophil cationic peptid, 25-hydroxyvitamin-D, IL-1beta, and sCD200 in a cases of samter's syndrome: 36 months follow-up. Immunopharmacol Immunotoxicol 2013;35(4):524-7
   Web of Science ®Google Scholar